The need for a correct oxygen-ozone autohemotherapy (O3-AHT) in patients with mild to moderate COVID-19 pneumonia
| Autor: | Sergio Pandolfi, Luigi Valdenassi, Dario Bertossi, Marianno Franzini, Salvatore Chirumbolo |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty 2019-20 coronavirus outbreak Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Ce - Letter to the Editor Pneumonia Viral Autohemotherapy Ozone Internal medicine Internal Medicine medicine Humans In patient Aged SARS-CoV-2 business.industry COVID-19 Middle Aged medicine.disease Pneumonia Phenotype Italy Case-Control Studies Emergency Medicine Female COVID-19 associated pneumonia business |
| Zdroj: | Internal and Emergency Medicine |
| ISSN: | 1970-9366 1828-0447 |
| DOI: | 10.1007/s11739-020-02592-w |
| Popis: | The emerging outbreak of the coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread worldwide. We prescribed some promising medication to our patients with mild to moderate pneumonia due to SARS-CoV-2, however such drugs as chloroquine, hydrossichloroquine, azithromycin, antivirals (lopinavir/ritonavir, darunavir/cobicistat) and immunomodulating agents (steroids, tocilizumab) were not confirmed as effective against SARS-CoV2. We, therefore, started to use auto-hemotherapy treated with an oxygen/ozone (O |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink